Resolving Inflammation Without Immunosuppression
Most available treatments used to treat inflammation suppress the immune system which can lead to a heightened risk of serious safety issues. Inflammation resolution strategies seek to provide both anti-inflammatory and pro-resolving activity without suppressing the immune system.
Harnessing the Melanocortin System to Resolve Inflammation
SynAct harnesses the melanocortin system to stimulate both anti-inflammatory and inflammation resolution mechanisms to resolve excessive inflammation safely without suppressing the immune system’s ability to respond to new infections or injuries.
Resomelagon (AP1189)
An Oral Selective Melanocortin Agonist
Our lead drug candidate resomelagon (AP1189) is a once-daily oral selective melanocortin agonist that selectively stimulates melanocortin receptors to help the body resolve inflammation. Resomelagon (AP1189) is being evaluated in rheumatoid arthritis (RA), idiopathic membranous nephropathy (iMN) and respiratory insufficiency caused by viruses like COVID-19.
-
April 24, 2024 RegulatoryBulletin from the extraordinary general meeting of SynAct Pharma AB
-
April 23, 2024 RegulatoryChanges in SynAct Pharma’s Nomination Committee ahead of the 2024 Annual General Meeting
SynAct Pharma AB published its year-end report for 2023 on February 23 at 07.30 CET.
Conference call and online presentation: the same day at 15.00 CET.
A MESSAGE FROM OUR CEO
“We have excellent opportunities ahead of us, and we remain focused on delivering patient, company and shareholder value.”